MeiraGTx(MGTX)
NEW YORK, NYBiotechnology
Focus: MeiraGTx is a New York-based gene therapy biotech focused on rare ocular and neurological diseases using AAV vectors. The company is publicly traded (MGTX) with early-stage pipeline assets across ophthalmology, neurology, and oncology indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
8-3 this month
Stable — net -3 jobs in 30d
2 added, 5 removed. Backfill posture.
Should You Work at MeiraGTx?
AI assessmentMeiraGTx offers early-stage gene therapy exposure with public company stability, but career advancement depends entirely on clinical success with no near-term regulatory catalyst in sight.
Why Work Here
- Meaningful impact on rare blindness: lead programs in achromatopsia, LCA, and retinitis pigmentosa address unmet needs in orphan ocular disease with only 11 active roles suggesting lean, focused team
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
16 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$33M
Key Products
AAV-CNGB3
Stable
Growth
Lead ophthalmology asset in Phase 1/2 for monogenic color blindness with unmet medical need.
AAV5-RPGR
Help build intelligence for MeiraGTx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.